



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

October 28, 2021

Werner Lanthaler  
Chief Executive Officer  
Evotec AG  
Essener Bogen 7  
22419 Hamburg  
Germany

**Re: Evotec AG**  
**Amendment No. 3 to Registration Statement on Form F-1**  
**Filed October 28, 2021**  
**File No. 333-260143**

Dear Dr. Lanthaler:

We have reviewed your amended registration statement and have the following comment.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our October 26, 2021 letter.

Amendment No. 3 to Registration Statement on Form F-1

Other Agreements with Novo Nordisk A/S

Evotec International Research Collaboration and License Agreement, page 157

1. We note your response to comment 1. Please revise your description of this agreement to more specifically quantify the payment provisions, including aggregate potential development milestone and sales milestone payments per product. Please note, while we are willing to accept a range for the royalty rate, disclosures such as "mid-double digit millions" and "low one hundred millions" for the development and sales milestones are not sufficient. Please revise to quantify each of these amounts on a per candidate basis.

You may contact Tracey Houser at 202-551-3736 or Brian Cascio at 202-551-3676 if you

Werner Lanthaler  
Evotec AG  
October 28, 2021  
Page 2

have questions regarding comments on the financial statements and related matters. Please contact Dillon Hagius at 202-551-7967 or Suzanne Hayes at 202-551-3675 with any other questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Sophia Hudson